ÂÜÀòÂÒÂ×

Dr. David L. Lacey served as a Director of argenx from 2014 to 2021, when he transitions to an advisory role. He has been a biopharmaceutical consultant since 2011, where he advises academic institutions, biotechnology companies and venture capital firms.

From 1994 until his retirement in 2011, he held various positions, including Head of Discovery Research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/RANKL/RANK pathway, which led to the development of the anti-RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA).

He holds a Bachelor’s degree in biology and an M.D. from the University of Colorado, and has his board certification in anatomic pathology.